investorscraft@gmail.com

Intrinsic value of Cardiovascular Systems, Inc. (CSII)

Previous Close$16.55
Intrinsic Value
Upside potential
Previous Close
$16.55

VALUATION INPUT DATA (original, your and others' valuations)

ParameterOrig.Your
Date of valuation (DoV)  
Intrinsic value (IV) at DoV, $/sh  
IV at current val. algorithm, $/sh13.45 

The original valuation is based on fiscal year data as of 2021-06-30 and quarterly data as of 2022-03-31.

Registered users can save their valuation input data

  1. Annual
  2. Quarterly YoY
  3. Quarterly QoQ

Annual revenue growth rates, % (past and forecasted)

NOTE: The bar chart shows historic and forecasted yearly revenue growth rates. Its purpose is to help you in determining what initial revenue rate you want to base your stock valuation on. Please make sure that you are confident in the value you select - for most stocks it is by far the most important parameter in valuation.

Company description

Cardiovascular Systems, Inc., a medical device company, develops and commercializes various devices to treat peripheral and coronary artery diseases in the United States. The company offers peripheral artery disease products, which are catheter-based platforms to treat a range of plaque types in above and below the knee leg arteries, including calcified plaque, as well as address various limitations related with surgical, catheter, and pharmacological treatment alternatives; and peripheral support products. It also provides Diamondback 360 Coronary orbital atherectomy systems (OAS), a coronary artery disease (CAD) product designed to facilitate stent delivery in patients with CAD who are acceptable candidates for percutaneous transluminal coronary angioplasty or stenting due to severely calcified coronary artery lesions. The company was founded in 1989 and is headquartered in St. Paul, Minnesota.

show cash flow forecast

FINANCIAL STATEMENTS FORECAST and PRESENT VALUE CALCULATION

Fiscal year2021(a)2022202320242025202620272028202920302031203220332034203520362037203820392040204120422043204420452046

INCOME STATEMENT

Revenue growth rate, %9.5NaN
Revenue, $259NaN
Variable operating expenses, $mNaN
Fixed operating expenses, $mNaN
Total operating expenses, $m271NaN
Operating income, $m-12NaN
EBITDA, $m-8NaN
Interest expense (income), $mNaN
Earnings before tax, $m-13NaN
Tax expense, $m0NaN
Net income, $m-13NaN

BALANCE SHEET

Cash and short-term investments, $m207NaN
Total assets, $m353NaN
Adjusted assets (=assets-cash), $m146NaN
Average production assets, $m46NaN
Working capital, $m230NaN
Total debt, $m23NaN
Total liabilities, $m82NaN
Total equity, $m271NaN
Debt-to-equity ratio0.084NaN
Adjusted equity ratio0.443NaN

CASH FLOW

Net income, $m-13NaN
Depreciation, amort., depletion, $m4NaN
Funds from operations, $mNaN
Change in working capital, $mNaN
Cash from operations, $m-1NaN
Maintenance CAPEX, $mNaN
New CAPEX, $mNaN
Total CAPEX, $m-4NaN
Free cash flow, $m3NaN
Issuance/(repurchase) of shares, $mNaN
Retained Cash Flow, $mNaN
Pot'l extraordinary dividend, $m230
Cash available for distribution, $mNaN
Discount rate, %NaN
PV of cash for distribution, $mNaN
Current shareholders' claim on cash, %NaN
HomeMenuAccount